Jeanelle S. King, PA-C, provides an in-depth look at nivolumab-relatlimab in a downloadable reference sheet.
Oncology Drug Crash Course: Nivolumab Plus Relatlimab (Opdualag)
Advertisement
Advertisement
Trending on Oncology Nursing News
1
FDA Approves Subcutaneous Daratumumab in High-Risk Smoldering Myeloma
2
Frontline Vaccine/Pembro Yields PFS Benefit in Advanced Melanoma
3
APP-Led Quality Assurance Group Is Feasible, Identifies Safety Events
4
What an Oncology APP Should Know About Exercise in Cancer Care
5
